BioSpace News Archive

Mainstay Medical Holdings plc announced that Jason Hannon, Chief Executive Officer, and Matthew Onaitis, Chief Financial Officer, will present a corporate overview at the LifeSci Partners Private Healthcare Company Virtual Summer Symposium on Wednesday, 5 August, 2020.

Collaboration aims to enable discovery of first-in-class therapeutic candidates

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Tuesday, August 4 at 8:30 a.m. ET to discuss the Company’s second quarter 2020 financial results and to provide a business

Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan drug designation for CTI-1601, a potential treatment for Friedreich’s ataxia (FA), a rare, progressive, multi-symptom genetic disease t

MOU to acquire 100% of privately held Sera Labs for $20 million, which consists primarily of stock with key earn out considerations totaling up to an additional $20 million within two years of completing the acquisition. Sera Labs brings to CURE a high-margin, retail and direct-to-consumer business with accelerating sales of its more than 20 products in the health & wellness, beauty, and pets categories and strong traction in both e-commerce and wholesale-to-retail distribution with to

The Chief Executive Officer for BetterLife Pharma Inc., recently joined investor portal Proactive to discuss the successful trial of another interferon inhalation treatment for COVID-19 similar to BetterLife’s AP-003 product, what this trial means for BetterLife, and what advantages AP-003’s interferon alpha2b may have over interferon beta treatments.

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of Bryan Laffitte , Ph.D., as Vice President, Biology. In his newly created role, Dr. Laffitte will be responsible for leading the company’s research and development

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020 , after the close of US markets. Management will host a conference call on the same

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it can now provide broader access to its growing inventory of plasma, serum and saliva specimens from active and recovered COVID-19 patients for use in drug, diagnostic and vaccine research.

SignPost Cancer Dx Inc., a company developing an advanced molecular diagnostic test to identify invasive breast cancer, is pleased to announce the filing of a provisional patent for the companys lead diagnostic test - BreastDefense. SignPost